Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00811512
Other study ID # sadalla1
Secondary ID
Status Completed
Phase N/A
First received December 18, 2008
Last updated December 18, 2008
Start date May 2007
Est. completion date October 2008

Study information

Verified date December 2008
Source Hospital de Olhos Sadalla Amin Ghanem
Contact n/a
Is FDA regulated No
Health authority Brazil: Ethics Committee
Study type Observational

Clinical Trial Summary

The goal is to describe the fundamental aspects of fundoscopic eye in patients with microphthalmia


Description:

Microphthalmos is a developmental ocular disorder defined as a small eyeball. The condition can be associated with abnormalities of anterior and posterior segments. The most common anterior characteristics include corneal opacities, angle-closure and a shallow anterior chamber and cataract. The main findings of posterior segment are uveal effusion, retinal folds, abnormalities of macular capillary vascularization, absence of foveal depression and peripheral retinoschisis. We performed on 3 patients with microphthalmos and their OCT features of posterior segment.


Recruitment information / eligibility

Status Completed
Enrollment 3
Est. completion date October 2008
Est. primary completion date September 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 10 Years to 80 Years
Eligibility Inclusion Criteria:

- Clinical diagnosis of microphthalmia

Exclusion Criteria:

- Eyes larger than 18mm

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Hospital de Olhos Sadalla Amin Ghanem
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03872479 - Single Ascending Dose Study in Participants With LCA10 Phase 1/Phase 2
Active, not recruiting NCT04123626 - A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene Phase 1/Phase 2
Completed NCT01727973 - Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy Phase 1/Phase 2
Completed NCT02946879 - Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)
Terminated NCT03913130 - Extension Study to Study PQ-110-001 (NCT03140969) Phase 1/Phase 2
Completed NCT03780257 - Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene Phase 1/Phase 2
Active, not recruiting NCT04765345 - Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F
Recruiting NCT05573984 - Natural History of PRPF31 Mutation-Associated Retinal Dystrophy
Recruiting NCT02203682 - Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy Phase 2
Completed NCT04945772 - Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE] Phase 2
Enrolling by invitation NCT06162585 - Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study
Active, not recruiting NCT05158296 - Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius) Phase 2/Phase 3
Completed NCT03396042 - Natural History Study of CEP290-Related Retinal Degeneration
Terminated NCT05176717 - Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste) Phase 2/Phase 3
Active, not recruiting NCT03913143 - A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) Phase 2/Phase 3